- Developed for aesthetic and dermatology clinics.
Launching with clinical partners in 2026.
Deliver advanced biologics.Without injections.
ExoGenis enables a biologic maintenance treatment that delivers fragile biologics into viable skin - without injections.
- Extend results between procedures
- No injections
- High-margin treatment layer
- No downtime
Powered by a proprietary biologic delivery platform.
ExoGenis fills the missing biologic maintenance layer between topical and injectable treatments.
Place biologics beyond the barrier predictably, in minutes, with no retained sharps.
- THE GAP IN TODAY’S CLINICS
Advanced biologics don’t fail. Delivery does.
Peptides, growth factors, and exosomes show strong clinical promise — but current delivery methods force clinics to choose between superficial topicals and invasive injections.
TOPicals
Blocked by the skin barrier
Most biologics never reach viable tissue.
Injectables
Precise but invasive
Time-intensive, risk-bearing, and unsuitable for frequent maintenance.
The Gap
No controlled option in between
Clinics lack a scalable way to extend results between procedures.
- The RESULt
A new category in biologic maintenance treatment.
ExoGenis is a biologic-compatible, dissolvable microneedle patch designed to complement — not replace — aesthetic and dermatology treatments.
- Controlled placement into viable skin layers
- Preserves biologic activity
- Fast in-clinic application
- Suitable for repeat and maintenance use
- Seamlessly integrates into existing workflows
topical application
Limited penetration
Most biologics stay on the surface depth-targeted deposition and dissolution-based release within viable epidermis.
exogenis patch
delivered
Designed to complement clinical procedures — not replace injectables
*Key risk addressed: biologic integrity during delivery
Controlled micro-channel formation, depth-targeted deposition and dissolution-based release within viable epidermis.
- Development roadmap
This is not concept - it’s early proof
Our journey towards bringing next-generation biologic delivery to aesthetic practices.
MVP & prototyping
Completed
Core dissolvable microneedle delivery system designed, built, and demonstrated in functional prototypes.
Technical validation
ongoing
Ongoing testing for reproducibility, stability, and performance optimization in Denmark.
Pilot manufacturing
next
Scale-up production processes and establish manufacturing partnerships.
Clinical pilots 2026
planned
Partner with select aesthetic clinics in Europe and UK for real-world validation.
Supported by leading innovation partners
.webp)
micro‑coating partner
.webp)
.webp)
.webp)
Interested in piloting ExoGenis?
We are looking for strategic partners in the professional skin care and dermatology space to join our exclusive pilot program.
Individual access coming soon.
Stay informed about our technology and future availability. Talk to us